Modeling of human factor Va inactivation by activated protein C
© Bravo et al.; licensee BioMed Central Ltd. 2012
Received: 15 February 2012
Accepted: 20 May 2012
Published: 20 May 2012
Because understanding of the inventory, connectivity and dynamics of the components characterizing the process of coagulation is relatively mature, it has become an attractive target for physiochemical modeling. Such models can potentially improve the design of therapeutics. The prothrombinase complex (composed of the protease factor (F)Xa and its cofactor FVa) plays a central role in this network as the main producer of thrombin, which catalyses both the activation of platelets and the conversion of fibrinogen to fibrin, the main substances of a clot. A key negative feedback loop that prevents clot propagation beyond the site of injury is the thrombin-dependent generation of activated protein C (APC), an enzyme that inactivates FVa, thus neutralizing the prothrombinase complex. APC inactivation of FVa is complex, involving the production of partially active intermediates and “protection” of FVa from APC by both FXa and prothrombin. An empirically validated mathematical model of this process would be useful in advancing the predictive capacity of comprehensive models of coagulation.
A model of human APC inactivation of prothrombinase was constructed in a stepwise fashion by analyzing time courses of FVa inactivation in empirical reaction systems with increasing number of interacting components and generating corresponding model constructs of each reaction system. Reaction mechanisms, rate constants and equilibrium constants informing these model constructs were initially derived from various research groups reporting on APC inactivation of FVa in isolation, or in the presence of FXa or prothrombin. Model predictions were assessed against empirical data measuring the appearance and disappearance of multiple FVa degradation intermediates as well as prothrombinase activity changes, with plasma proteins derived from multiple preparations. Our work integrates previously published findings and through the cooperative analysis of in vitro experiments and mathematical constructs we are able to produce a final validated model that includes 24 chemical reactions and interactions with 14 unique rate constants which describe the flux in concentrations of 24 species.
This study highlights the complexity of the inactivation process and provides a module of equations describing the Protein C pathway that can be integrated into existing comprehensive mathematical models describing tissue factor initiated coagulation.
KeywordsCoagulation Factor Va Activated protein C Prothrombinase Prothrombin Factor Xa Mathematical modeling
It is critical that once a procoagulant response to vascular injury has been initiated that an appropriate anticoagulant response is concurrently mounted. As such, the components of the prothrombinase complex are targets of multiple regulatory mechanisms to terminate the production of thrombin. First, FXa availability is regulated by formation of inhibition complexes with antithrombin (AT), α1-antitrypsin, and tissue factor pathway inhibitor (TFPI) [10, 11]. The cofactor, FVa, is a target for degradation by activated protein C (APC). APC, a serine protease derived from its plasma precursor protein C (PC) in a thrombin dependent process , plays a critical role in inactivating the non-enzymatic cofactor components of both the prothrombinase and the intrinsic tenase complexes, factors Va and VIIIa, respectively [13–15]. Additional key components of the PC pathway include: thrombomodulin and endothelial protein C receptor (EPCR) which contribute to APC formation ; protein S which functions as a cofactor enhancing APC efficacy ; and protein C inhibitor, a suppressor of APC formation [18, 19].
An increased risk of thrombotic disease has been associated with partial deficiencies or loss of function mutations in the PC pathway, including deficiencies in PC, its cofactor protein S, or proteins involved in the activation of PC . The most prevalent defect in the PC pathway is a result of a genetic mutation in FV that renders the cofactor resistant to APC inactivation . This resistance to APC was first characterized by Dahlbäck and coworkers  and derives from a mutation at one of the APC inactivation sites (Arg506 → Gln506) on FV/FVa rendering it resistant to APC cleavage .
APC catalyzed inactivation of FVa cofactor activity is a complex, membrane dependent process involving cleavage at multiple sites in the FVaHC, the generation of transient species with partial cofactor activity, and the ultimate disassociation of a fragment of the FVaHC from the molecule rendering it catalytically inactive. APC interacts with FVa or partially proteolyzed FVa species through their light chains to form enzymesubstrate complexes [23–25]. Additional studies have identified other regions of interaction, including the proteolytic target residues and the surrounding regions, in the FVa heavy chain involved in the enzymesubstrate complex formation [26–28]. Three arginine residues are targeted in human APCFVa complexes: Arg306, Arg506, and Arg679[15, 29]. A number of studies have defined the activities of the partially proteolyzed FVa species [30, 31]. Cleavage at either Arg306 or Arg506 results in cofactor species, FVai306 and FVai506, respectively, with reduced but similar cofactor activity in the prothrombinase complex (Figure 1) [30, 31]. Cleavage at Arg306 has been shown to be essential for full loss of cofactor activity . The significance of the cleavage at Arg679 remains undetermined. The final inactive cofactor, FVai, is a two chain molecule composed of the FVaLC and FVa1-306 fragment (Figure 1) . The inactive cofactor binds APC with the same affinity as the intact cofactor [23, 33], suggesting a potential role of product inhibition in regulating APC efficacy .
Numerous studies examining how components like FXa, prothrombin and protein S modulate APC inactivation of FVa have been reported [14, 34–40]. These studies routinely employ approaches like progress curve analysis based on curve fitting to compare initial rates, or natural and recombinant cleavage site mutants to detail mechanistic features. To date, however, an integrated approach, one combining the use of physicochemical model construction based on prior research and model verification via construction of corresponding reaction systems using purified proteins, has not been extended to understand APC regulation of the prothrombinase complex stability and function. In this study we build on the prior studies modeling APC inactivation of FVa  by incorporating the presence of additional components of the prothrombinase complex (FXa and prothrombin) to construct an empirically validated mathematical model. To test model constructs, a step-wise approach to increasing the number of components was used. Experiments were replicated multiple times with different preparations of proteins in order to generate robust data sets that included estimates of measurement error. At each level of complexity, we empirically monitored multiple analytes, including starting reactants, intermediates and final products to provide multiple points of comparison to evaluate each model’s performance.
Results and Discussion
APC Inactivation of Factor Va
Western blot analyses (representative blot in Figure 3, Panel B) monitoring the disappearance of intact FVaHC (residues 1–709) display the rapid proteolysis of FVa heavy chain proteolyzed at either site within the first or third minutes with 2.0 or 0.5 nM APC, respectively (Figure 3, Panel C, red and black circles, respectively). These results were each fit to monophasic exponential decays (fit not shown), and the initial slope of the fitted curve was determined after normalizing the densitometry to the maximal value (RMV). At 0.5 nM APC, the initial rate of disappearance of the heavy chain was 200 pM/s (based on 20 nM starting concentration); at 2.0 nM APC, the rate of disappearance was nearly three-fold faster (558 pM/s). The disappearance of the heavy chain is initially concurrent with accumulation of the FVa1-506 fragment (Figure 3, Panel D). The generation of the FVa1-506 fragment reaches a maximum within 30 sec (2.0 nM APC) or 90 sec (0.5 nM APC) (Figure 3, Panel D, red and black circles, respectively). At this point most of the FVaHC has been proteolyzed primarily at Arg506, and the secondary cleavage at Arg306 in the FVa1-506 species becomes the dominant proteolytic event. Analysis of the appearance of the inactivation fragment FVa307-506 (resulting from cleavage at both Arg306 and Arg506, Figure 3, Panel E), indicates that as the FVa1-506 fragment is approaching its maximum level it is being further proteolyzed to the FVa307-506 fragment. In order to isolate the kinetics of proteolysis at Arg306, FVai506 was used as the starting material in inactivation studies with 0.5 nM APC (Figure 3, Panel F, open circles). This membrane bound partially proteolyzed species has already lost most of its cofactor activity in a clotting assay [30, 31, 33]. Tracking of the final inactivation fragment, FVa307-506, by Western blotting reveals a monophasic accumulation of this fragment (fit not shown) (Figure 3, Panel F).
Equations describing APC inactivation of factor Va
APC + FVa ← 2-1 → APCFVa
1 x 108
APCFVa −3 → APC + FVai506
APCFVa −4 → APC + FVai306
APC + FVai506 ← 2-1 → APCFVai506
1 x 108
APC + FVai306 ← 2-1 → APCFVai306
1 x 108
APCFVai506 -4 → APC + FVai306/506
APCFVai306 -3 → APC + FVai306/506
FVai306 -5 → FVa1-306FVaLC + FVa307-679/709
FVai306/506 -5 → FVa1-306FVaLC + FVa307-506 + FVa507-679/709
APC + FVa1-306FVaLC ← 2-1 → APC FVa1-306FVaLC
1 x 108
However, the predicted generation and disappearance of the FVa1-506 fragment are significantly delayed compared to the empirical data for this inactivation fragment (Figure 3, Panel D, black dashed line vs. black circles). At 0.5 nM APC, the simulation predicts that this fragment will reach a maximum at 3.4 min before slowly disappearing, with 30 % still remaining after 20 min; the empirical experiments show the peak level reached at 1.5 min with only 9 % remaining after 20 min (Figure 3, Panel D, black dashed line vs. black circles). The mathematical simulation fared better with 2.0 nM APC (Figure 3, Panel D, red dashed line vs. red circles) with respect to the timing of peak accumulation, however failed to recapitulate the rapid clearance of this fragment. Mathematical simulations of FVa307-506 using the Hockin et al.  rate constants resulted in an estimated six-fold slower accumulation of this fragment compared to empirical data (Figure 3, Panel E, dashed lines vs. circles).
Though the bovine based Hockin et al.  rate constants clearly captured the disappearance of FVaHC as measured through activity and fragment analysis, they did not accurately predict the presentation of either the FVa1-506 or FVa307-506 fragments in the human system. The rapid clearance of the FVa1-506 fragment and faster appearance of the smaller FVa307-506 fragment led us to speculate that their model rate constant for the cleavage at Arg306 was not appropriate for the human system of proteins. From a comparison of the empirical data to the initial in silico simulation we estimated that the rate of cleavage occurring at Arg306 was three times faster than the model predictions. To account for this the rate constant (Figure 2, k4; Table 1, Eqns 3 and 6) in the mathematical model was adjusted from 0.064 s-1 to 0.192 s-1 and simulations rerun for all analytes (Figure 3, solid lines). As expected the simulated predictions for FVa cofactor activity and FVaHC were minimally altered by this change and continued to correlate well with their respective empirical measures (Figure 3, Panels A and C, solid lines vs. filled circles). The adjusted rate constant significantly altered the in silico predictions for both smaller FVa inactivation fragments (Figure 3, Panels D and E, solid lines vs. dashed lines) yielding a better fit with empirical results. The revised model using the adjusted kinetic rate was extended to experiments conducted with FVai506 and the predicted time courses for the two models compared to the empirical results (Figure 3, Panel F, solid lines and dashed lines vs. open circles). As can be seen in all simulations, those using the published bovine model values (Figure 3, dashed lines) resulted in a poorer fit . The rate constant for cleavage at Arg306, k4, was adjusted to 0.192 s-1 for all subsequent studies.
Our empirically driven adjustment to k4 results in a second order rate constant for the overall process of cleavage at Arg306 of 2.74 x 107 M-1 s-1. Previously published second order rate constants for the APC cleavage at Arg306 in human FVa (1.55 x 106 M-1 s-1, 1.7 x 106 M-1 s-1, and 2.5 x 106 M-1 s-1) are an order of magnitude lower than our currently derived estimate and lower than that used by Hockin et al. (9.1 x 106 M-1 s-1) to describe the bovine system.
Studies using human proteins on APC inactivation of FVa reported second order rate constants for the cleavage at Arg506 ranging from 3.0-4.3 x 107 M-1 s-1[31, 41]; a more recent study by Nicolaes et al.  has reported the second order rate constant to be 1.17 x 108 M-1 s-1. This value is quite similar to the value (1.42 x 108 M-1 s-1) used in the current study.
An alternative approach to fitting these data sets would have been to use an optimization method in which all rate constants may be simultaneously adjusted to generate a best fit to all the experimental data. Failure of model predictions to fit the empirical data can stem from the collective effect of small errors in the rate constants used. It is not uncommon for laboratories to report 2–3 fold differences in rate constants of biochemical reactions and interactions measured in vitro. These ranges are accepted because the findings would fall within the margin of error expected for slightly variable experiments conducted in different laboratories, or for different techniques used to measure a rate constant. Such variation can have significant effects on model outputs . However, lack of fit can arise from a fundamental mistake or omitted interaction in the reaction description. Therefore, we have not taken this approach as we developed this model.
APC Inactivation of Factor Va: Effect of Factor Xa Under Non-saturating Conditions
It has been widely reported that FXa shields FVa from degradation by APC through its reversible association in the prothrombinase (FXaFVa) complex [34–38, 44]. The mechanistic basis of this protection has been conceptualized as a mutually exclusive competition for association with membrane bound FVa, so that when FVa is associated with FXa it is not a substrate for APC , at least at the Arg506 site . In order to develop a model description that can predict the extent of the protective effect exerted by FXa against APC proteolysis of FVa over a range of reactant concentrations, empirical experiments were performed at saturating and non-saturating concentrations of FXa.
Equations describing interactions between intact and partially proteolyzed factor Va with factor Xa and prothrombin
FXa + FVa ← 7-6 → FXaFVa
0.2 a 0.075 b
4 x 108 a
1.5 x 108 b
FXa + FVai506 ← 8-6 → FXaFVai506
4 x 108 c
1.5 x 108 b
FXa + FVai306 ← 8-6 → FXaFVai306
4 x 108 c
1.5 x 108 b
FXa + FVai306/506 ← 8-6 → FXaFVai306/506
4 x 108 c
1.5 x 108 b
FXaFVai306 -9 → FXa + FVa1-306FVaLC + FVa307-679/709
FXaFVai306/506 -9 → FXa + FVa1-306FVaLC + FVa307-506 + FVa507-679/709
FVa + PT ← 11-10 → FVaPT
1 x 108
Our initial mathematical simulations were carried out utilizing a KD of 0.5 nM , resulting in an initial concentration of 26 pM for prothrombinase, with off and on rates of 0.2 s-1 and 4.0 x 108 M-1 s-1, respectively (Table 2, Eqn 11) [46, 47]. The mathematical predictions for the loss of prothrombinase activity in the presence of either 0.5 or 2.0 nM APC showed an approximately 2-fold faster loss in prothrombinase activity than observed in the empirical experiments (Figure 4, Panel A, dashed lines vs. filled circles).
To generate a better fit to the empirical data we first examined the dissociation constant of FXa and FVa on PC:PS vesicles, which by literature reports varies from as low as 83 pM  to as high as 1 nM . Simulations to test the wide range of reported KD values were first conducted by altering the koff rate constants for the prothrombinase complex, while maintaining the same kon rate constant of 4.0 x 108 M-1 s-1. For each KD value tested, the starting concentrations of free and bound species (FVa, FXa, and FXaFVa) were recalculated and used as the initial conditions for a mathematical simulation. An adjustment made to the off rate for the prothrombinase complex resulting in a KD of 0.1 nM (58.8 pM prothrombinase initially) generated an in silico prediction that more closely represented the empirical results seen with both 0.5 and 2.0 nM APC (Figure 4, Panel A, black and red, respectively, dotted lines vs filled circles).
In addition to altering the koff rate constant while maintaining a kon rate constant to reach a desired overall KD, changes to both isolated rate constants were explored as a potential solution. One alternative that we explored was adjusting the kon rate constant to 1.5 x 108 M-1 s-1 and setting the koff rate constant to values that yielded the same set of KD values. Figure 4, Panel B presents these model results at 0.5 and 2.0 nM APC (black and red, respectively) for KD's of 0.5 nM (dashed lines) and 0.1 nM (dotted lines) for prothrombinase assembly. In contrast to simulations based with a kon value of 4.0 x 108 M-1 s-1 this analysis indicates that a KD of 0.5 nM yields a better fit to the data.
These results highlight an important feature of dynamic systems like this one: the magnitude of the observed protective effect may depend not only on the concentrations of the three protein components and the KD's characterizing their interactions, but also on the rate constants defining the competing KD's.
APC Inactivation of Factor Va: Effect of Factor Xa Under Saturating Conditions
Figure 5 presents empirical experiments in which preformed prothrombinase (20 nM FVa and 30 nM active site blocked FXa (FXa*)) was treated with 2.0 nM APC and time courses of FVaHC and its APC-derived fragments FVa1-506, FVa307-679/709 and FVa307-506 visualized by Western blotting (Figure 5, Panel A, inset). Under these conditions, 95 % to 99 % of the FVa is bound to FXa* prior to addition of APC given KD values in the range of 0.5 nM to 0.1 nM, respectively. The selection of 20 nM FVa reflected the fact that in closed model systems of TF-initiated coagulation, levels of FVa reach 20 nM  and the practical requirement for a concentration suitable for Western blot analysis. Active site blocked FXa was used to prevent FXa proteolysis of FVa .
Reactions where the FVa population is highly associated with FXa* showed 70 % of FVaHC remained after 1 minute (Figure 4, Panel C and Figure 5, Panel A, red circles) compared to ~ 10 % without FXa* (Figure 3, Panel C, red circles). Comparison of initial rates showed a greater than 7-fold reduction in the initial rate of 2.0 nM APC proteolysis of FVa due to its FXa association (77 pM/s vs. 558 pM/s). Consistent with this overall suppression of heavy chain proteolysis, generation of the FVa1-506 fragment was slower in the presence of FXa*, reaching a maximum in 2 min vs ~30 s in its absence (Figure 5, Panel B vs. Figure 3, Panel D, red circles). Its clearance was also suppressed, taking ~ 4 min to decline to 50 % of its maximum as opposed to ~1 min without FXa* (Figure 5, Panel B vs. Figure 3, Panel D, red circles).
In contrast to APC inactivation studies conducted in the absence of FXa*, visual inspection of Western blot images (Figure 5, Panel A, inset) reveal the accumulation of the FVa307-679/709 fragment leading to more reliable quantitative densitometric analysis of this fragment (Figure 5, Panel C, red circles). Generation of this fragment reaches 50 % of its maximal level by 1 minute, and remains at elevated levels above 70 % of maximal level after 2 minutes (Figure 5, Panel C, red circles). Generation of the FVa307-506 fragment reaches 50 % of maximal value after 3 minutes (Figure 5, Panel D, red circles).
Initial prothrombinase concentrations given the condition of pre-incubating 20 nM FVa and 30 nM FXa* were calculated to be 19.1 nM or 19.8 nM using KD values of either 0.5 nM or 0.1 nM, respectively. A range of kon and koff rate constants for each KD were tested by varying kon values between 1 and 4.0 x 108 M-1 s-1. Time courses of the inactivation of FVa by 2.0 nM APC were produced. The results of this in silico study indicated that the disappearance of FVaHC was dependent on the resultant KD value and independent of the combination of kon and koff rate constants used to generate the KD values of 0.1 or 0.5 nM (data not shown). Assuming the KD for prothrombinase is 0.1 nM and the kon is either 1.5 x 108 M-1 s-1 or 4.0 x 108 M-1 s-1, the model predicts that after 6 min 25 % of the FVaHC is proteolyzed (Figure 4, Panel C, red dotted line), in contrast to the empirical results showing ~82 % of FVaHC proteolyzed at 6 minutes (Figure 4, Panel C, red circles). Model simulations with KD values of 0.5 nM, 0.75 nM or 1.0 nM resulted in FVaHC levels decreasing after 6 min by 75 % (Figure 4, Panel C, red dashed line), 83 % (Figure 4, Panel C, red solid line), or 87 % (data not shown), respectively. From the mathematical simulations, the initial rates of FVaHC proteolysis were 22 pM/s, 86 pM/s, and 122 pM/s for KD’s of 0.1 nM, 0.5 nM, and 0.75 nM, respectively, compared to the empirically derived rate of FVaHC proteolysis of 78 pM/s. Overall these comparisons support our eliminating 0.1 nM as the KD for the prothrombinase complex.
While the mathematical model is able to recapitulate the overall combined initial cleavages of FVaHC (Figure 5, Panel A, dotted line vs. filled circles), there is a mixed success for the predictions of the inactivation fragments (Figure 5, Panels B-D, dotted line vs. filled circles). Specifically, the mathematical model captures the rapid accumulation of the FVa307-679/709 fragment (Figure 5, Panel C, dotted line), but does not capture the clearance of the FVa1-506 fragment (Figure 5, Panel B, dotted line) or the generation of the FVa307-506 fragment (Figure 5, Panel D). The same lack of fit for the proteolysis of this fragment is observed when FVai506 is the starting substrate (Figure 5, Panels E and F, dotted line vs. filled circles).
In the mathematical model as constructed APC proteolysis at any site is permitted only with FVa species not bound to FXa (or FXa*). The more rapid clearance of FVa1-506 observed empirically suggests two possible problems with the model construct: 1) the binding affinity between FVai506 and FXa is weaker than the model value of 1 nM based on studies with bovine FVa  or 2) APC can cleave at Arg306 when the FVai506 species is bound to FXa. Previous studies with recombinant human proteins have reported KD values ranging from ~3.9 nM  to ~1.35 nM . To evaluate the likelihood that a weaker binding affinity was the culprit, mathematical simulations were conducted where the KD for the FXaFVai506 complex was varied; to fit the empirical data the KD for this complex would have to be greater than 10 nM (data not shown) and as such this adjustment was discarded as a viable option.
The alternative explanation for the empirical data presenting the clearance of the FVa1-506 fragment is that when bound to FXa, the FVai506 species is susceptible to APC cleavage at Arg306. To explore this hypothesis, an additional reaction was added to the mathematical construct: APC cleaving (FXaFVai506) at Arg306. To establish whether there was a value for this rate constant that would improve the fit, simulations varying its value were run using the model value (2.7 X 107 M-1 s-1) for the cleavage of Arg306 in free FVa as a point of reference. Representative examples are presented in Figure 5. The mathematical analysis suggests that if the Arg306 in (FXaFVai506) is a target for APC, the magnitude of the rate constant regulating the event is ~10 to 20 % that for free FVa.
APC Inactivation of Factor Va: Effect of Prothrombin
In addition to the protection afforded to FVa by FXa in the prothrombinase complex, the substrate of the complex, prothrombin (PT), has also been shown to inhibit APC inactivation of FVa [39, 40, 58]. Guinto and Esmon reported that prothrombin protects the intact FVa molecule by competing with APC for binding to FVa ; more recent studies have reported a KD of between 500–700 nM for FVa and prothrombin [39, 40].
An additional reaction describing the reversible formation of the FVaPT complex with a KD of 700 nM  was added to the ordinary differential equation (ODE) network (Table 2, Eqn 17). The initial concentration of preformed FVaPT complex, given 20 nM FVa and 1.4 μM PT, was calculated to be 13.3 nM. Simulated time courses for FVa heavy chain fragments generated by APC (2.0 nM or 20.0 nM, red and blue lines, respectively) proteolysis did not correlate well with the empirical data, in fact suggesting that there would be little to no protection of FVa by 1.4 μM prothrombin if the KD was 700 nM (Figure 7, Panel A, dashed with dotted lines vs. filled circles; Note, red dashed with dotted line is underneath blue dashed line). Test simulations varying the KD were performed by altering the koff constant for the equilibrium describing the prothrombin and FVa interaction. Even when a KD of 50 nM was assigned to the interaction, ~ 10-fold less than published estimates  the resulting simulations did not capture the observed level of protection (data not shown).
In the computational model one of the assumptions is the presence of unlimited binding sites located on a single surface so that competition between proteins for occupancy of the phospholipid surface is not a factor. At 20 μM PC:PS vesicles, and setting the phospholipid/protein binding site ratio between 30 and 60 [59–61], available binding sites fall in a range between 220 and 440 nM. The simultaneous solution of the equilibrium expressions for prothrombin, FVa, and APC (defined as non-catalytic) binding to phospholipid membrane with KD’s of 230 nM , 2.72 nM , and 500 nM , respectively, shows that between 77–78 % of binding sites are occupied by prothrombin, over 96 % of the FVa is bound, and only approximately 11 % of the APC is able to bind to the surface whether 2.0 or 20.0 nM APC is present. By using this bound fraction of APC as the catalytically relevant population, the mathematical simulations better captured the kinetics of FVHC proteolysis in the presence of 1.4 μM prothrombin (Figure 7, Panel A, solid lines vs. filled circles). Similarly, comparison of empirical and simulated time courses for the three generated fragments (Figure 7, Panels B-D, filled circles vs. solid lines) also show improved fits. Our findings indicate that there may in fact be a tighter association between FVa and PT, in line with the findings of Yegneswaran et al. (Figure 7. Panel A, filled circles vs. dashed lines) .
To verify that the impaired FVa proteolysis observed under the empirical reaction conditions was not solely due to competition for phospholipid binding sites, mathematical simulations were constructed using the adjusted APC concentration, but without permitting the formation of the FVaPT complex. This model construct failed to predict the time courses for FVaHC disappearance and the fragments FVa1-506 and FVa307-679/709 (Figure 7, Panel A, B and C, filled circles vs. dotted lines). Thus the computational studies indicate that the prothrombin dependent suppression of FVa proteolysis by APC observed in our empirical reactions is due both to binding site competition (prothrombin membrane association limiting APC access to the membrane surface) and to the FVaPT complex not being a substrate for APC. Comparisons of the empirical data for FVaHC proteolysis (Figure 7, Panel A) with the simulations representing unlimited binding sites (dashed with dotted lines), limited binding site adjustment but no FVaPT interaction (dotted line) and the limited binding site adjustment with FVaPT complex formation (KD = 700 nM) (solid line) indicate that under these conditions approximately half of the observed PT dependent suppression is due to FVaPT complex formation.
APC Inactivation of Factor Va: Effect of Prothrombin and Saturating Levels of Factor Xa
Addition of 2.0 nM APC to the reaction system led to only 39 % of the FVaHC being proteolyzed after 20 minutes (Figure 9, Panel B, red circles). The initial rate of disappearance was 14 pM/s, nearly 41-fold lower than the inactivation rate in the absence of both prothrombin and FXa (558 pM/s; Figure 3, Panel A, red circles). Inactivation studies with 10 times more APC resulted in a nearly 8-fold increase in the initial rate of inactivation (100 pM/s) (Figure 9, Panel B, blue circles).
Equations describing interactions between catalytically inactive prothrombinase species and prothrombin
FXaFVa + PT ← 14-13 → FXaFVaPT
1.0 x 108 a
FXaFVai506 + PT ← 14-13 → FXaFVai506PT
1.0 x 108
FXaFVai306 + PT ← 14-13 → FXaFVai306PT
1.0 x 108
FXaFVai306/506 + PT ← 14-13 → FXaFVai306/506PT
1.0 x 108
FXaFVai306PT −9 → FXa + FVa1-306FVaLC + FVa307-679/709 + PT
FXaFVai306/506PT −9 → FXa + PT + FVa1-306FVaLC + FVa307-506 + FVa507-679/709
Simulated time courses for the disappearance of the FVaHC were generated for the experiments where 2.0 nM or 20.0 nM APC was added. Based on the findings from the APC inactivation studies of FVa in the presence of prothrombin, APC effective concentrations were adjusted to 11 % of the total to account for the limited binding sites (Figure 9, Panel B, solid lines). The simulations’ initial rates of proteolysis of the FVaHC (6 pM/s) were less than half the measured empirical rates (14 pM/s). The mathematical simulations greater level of protection extends through 20 minutes with higher amounts of FVaHC anticipated compared to empirical results (2.0 nM APC: 76 % vs. 61 %, respectively; 20.0 nM APC: 26 % vs. 11 %, respectively) (Figure 9, Panel B). Empirical studies were also conducted with 50 μM PC:PS vesicles and did not result in any significant changes in the initial rate or overall time course of FVaHC proteolysis by 2.0 nM APC (data not shown), suggesting that under the current conditions, phospholipid membrane accessibility is not impeding the inactivation reaction.
Potential explanations for this disparity include: 1) accumulated effect of small errors in rate constants; 2) improved binding of APC to the surface; 3) a misestimate of the affinity of the prothrombinase prothrombin interaction; and 4) the affinity of human APC for FVa is slightly higher, e.g. the KD is less than 7 nM. Additional experiments will be required to distinguish between these possibilities. It is important to note that phospholipid composition plays an important role in protein-membrane interactions which can extend to effects on enzyme activity (Reviewed in ). Several studies have directly highlighted the effect of membrane composition on the APC inactivation of FVa [66–68].
Reagents and Proteins
Human prothrombin and Factor X were isolated according to methods as described . Factor Xa was prepared as previously described using Russel’s Viper Venom Factor Xa Activator [82, 83]. Human Factor V was purified from citrated plasma according to previously described procedures . Activated human protein C was purchased from Haematologic Technologies, Essex Junction, VT. 1,2-Dioleolyl-sn-Glycero-3-Phospho-L-Serine (PS) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (PC) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL) and phospholipid vesicles (PC:PS) composed of 75 % PC and 25 % PS were prepared as described [60, 84]. Spectrozyme TH and recombinant hirudin were purchased from American Diagnostica, Inc (Greenwich, CT) and EDTA was purchased from Sigma (St Louis, MO). D-Phe-Pro-ArgCH2Cl (FPRck) was prepared in house. Monoclonal anti-fV (αHFV#17) was obtained from the Biochemistry Antibody Core Laboratory (University of Vermont) and a goat anti-mouse IgG conjugated to HRP was purchased from Southern Biotech (Birmingham, AL). Active site blocked FXa (FXa*) was produced according to the previously published method .
Multiple preparations of FV/FVa and different lots of APC were utilized for these studies. Preparations of Factor Va were made fresh prior to all experiments. Factor V (1.0 μM) in 0.2 M HEPES, 0.15 M NaCl, 0.1 % PEG-8000, 2.0 mM CaCl2, pH 7.4 (HBS-PEG-Ca) was activated with 10 nM human thrombin for 10 min at 37°C. Thrombin activation was stopped by addition of 12 nM recombinant hirudin and placing the sample on ice. Factor Va preparations were used within 4 hours. The partially proteolyzed species of factor Va cleaved only at Arg506 was generated by incubating FVa (750 nM) in HBS-PEG-Ca with 5.0 nM APC for 20 minutes at 37°C, after 20 minutes an additional 5.0 nM APC was added. Following the inactivation reaction, the FVai506 containing reaction was placed on ice and incubated with 1.0 mM di-isopropyl phosphate to inactivate the APC.
Inactivation of Factor Va by Activated Protein C
Solutions of factor Va (20 nM) in HBS-PEG-Ca with 20 μM PC:PS were prepared at 37°C. At the zero time point 0.5 or 2.0 nM APC was added to the FVa solution. At designated intervals samples were removed, and either quenched in denaturing sample preparation buffer (0.31 M Tris[hydroxymethyl]aminomethane, 10 % sodium dodecyl sulfate, 50 % glycerol, 0.5 % Bromophenol Blue, pH 6.8) and analyzed either for proteolytic cleavage using SDS-PAGE and subsequent immunoblot analysis (Western blotting), or for co-factor activity using a one-stage clotting assay in factor V deficient plasma. Inactivation reactions were diluted 40-fold in an appropriate volume of factor V deficient plasma and assayed immediately. Clotting activity is represented as a percentage of the clotting time observed for unproteolyzed FVa.
Inactivation of Factor Va by Activated Protein C in the Presence of Factor Xa
Rates of APC inactivation of FVa (0.2 nM) in the presence of PC:PS vesicles (20 μM) and FXa (0.1 nM) were assessed with the prothrombinase complex preformed for five minutes at 37°C in HBS-PEG-Ca. At the zero time point APC (0–2.0 nM) was added to the prothrombinase complex solution. At designated intervals aliquots were removed and added to a minimal amount of concentrated prothrombin (1.0 μM final). After 90 s, aliquots were quenched with the addition of 0.5 M EDTA (25 mM final) and subsequently monitored for thrombin activity against the chromogenic substrate SpecTH. Thrombin concentrations were determined by reference to a standard curve and the level of thrombin generated used as a relative measurement of prothrombinase concentration compared to measurements with intact FVa.
Prothrombinase complex was preformed on 20 μM PC:PS vesicles in HBS-PEG-Ca for four minutes at 37°C using 30 nM fluorescein-active site blocked FXa (FXa*) and 20 nM FVa. A sample aliquot was removed, APC added (2.0 nM), aliquots taken at selected time points and quenched into denaturing sample preparation buffer, and subsequently analyzed by Western blotting.
Inactivation of Factor Va by Activated Protein C in the Presence of Prothrombin
Reaction mixtures of FVa (20 nM) and prothrombin (1.4 μM) were prepared with 20 μM PC:PS vesicles in HBS-PEG-Ca and incubated for four minutes at 37°C. A sample aliquot was removed, APC added (2.0 or 20.0 nM), aliquots taken at selected time points and quenched into denaturing sample preparation buffer, and subsequently analyzed by Western blotting.
Inactivation of Factor Va by Activated Protein C in the Presence of Prothrombin and Factor Xa
Reaction mixtures of FVa (20 nM), fluorescein-active site blocked FXa (FXa*, 30 nM), and prothrombin (1.4 μM) were prepared with 20 μM PC:PS vesicles in HBS-PEG-Ca and incubated for four minutes at 37°C. A sample aliquot was removed, APC added (2.0 or 20.0 nM), aliquots taken at selected time points and quenched into denaturing sample preparation buffer, and subsequently analyzed by Western blotting.
Western blotting and densitometric analyses
All FVa samples were run under reducing conditions. FVa heavy chain and inactivation fragments were analyzed by fractionation on 4-12 % SDS-PAGE acrylamide slab gels followed by electrophoretic transfer of proteins to Immobilon-FL membranes (Millipore Inc., Billerica, MA), and detected using a mouse monoclonal antibody (αHFV#17) that binds to an epitope between residues 307–506 of the factor Va heavy chain and a goat anti-mouse IgG conjugated to HRP (Southern Biotech). Luminescence was detected using a Fuji LAS-4000 in conjunction with ImageCapture software (Fujifilm, Tokyo, Japan). Densitometry was carried out using MultiGauge software (Fujifilm, Tokyo, Japan). For each species, densitometric values at each time point were normalized to their maximal value during the time course.
The description using ordinary differential equations of the reaction pathway for bovine APC inactivation of bovine FVa reported by Hockin et al.  was used as a starting framework (Figure 2; Table 1). The scheme describes a random order cleavage process for Arg306 and Arg506 in which the cleavages are independent of each other and characterized by substantially different rate constants. Our simulator employs a fourth order Runga-Kutta algorithm to generate a series of time-dependent concentration profiles for all reactants, intermediates, and products.
Factor Va cofactor activity will be represented by the cumulative presence of FVaHC species present at any point in time. For measurements of prothrombinase activity, the sum of all FVa species was added to the weighted (20 %) sum of FVai306, FVai506, and FVai306/506. Factor Va inactivation fragments will be represented by including respective fragments both associated and dissociated from the FVaLC.
To generate an appropriate simulation of the empirical experiment where FXa and FVa are pre-incubated together on the phospholipid surface to form the prothrombinase complex prior to the addition of APC, the concentrations of free FXa and FVa, and the prothrombinase complex were solved. For example, studies with 200 pM FVa and 100 pM FXa, for each potential KD (e.g. 0.1 nM or 0.5 nM, respectively), the values of the three initial conditions ranged from 41–74 pM for free FXa, 141–174 pM for free FVa, and 59–26 pM for prothrombinase. The concentrations of the three species then served as the initial conditions in the simulations in conjunction with either APC concentration.
In silico simulations were carried out with the initial concentrations used in the empirical experiments and the relevant output calculated and compared to the appropriate analyte measured in the empirical experiments.
Activated protein C
(Ethylene-dinitrilo) tetraacetic acid
Activated factor V
Heavy chain of FVa
Light chain of FVa
A two chain molecule composed of the FVaLC and FVa1-306 fragment
Activated factor X
Active site-blocked activated factor X
20 mM HEPES, 150 mM NaCl, pH 7.4
PS vesicles: Single bilayer phospholipid vesicles composed of 75 % 1,2-dioleoyl-sn-glycero-3-phosphocholine and 25 % 1,2-dioleoyl-sn-3-glycero-3-[phospho-L-serine]
Polyethylene glycol, average molecular weight = 8000
Relative to maximal value
This paper was supported by F31 GM 81904 (MCB), R01 HL 034575 (KGM), and P01 HL 46703 (KGM) from the National Institute of Health. Additional support was provided by contract W911NF-10-1-0376 (KGM) from the Department of Defense. Additional support was provided by NEAGEP at the University of Vermont (MCB), institutional funds from the College of Medicine at the University of Vermont (MCB), and the Department of Biochemistry at the University of Vermont (MCB, SJE).
- Esmon CT, Suttie JW, Jackson CM: The functional significance of vitamin K action. Difference in phospholipid binding between normal and abnormal prothrombin. J Biol Chem 1975, 250: 4095-4099.
- Nesheim ME, Taswell JB, Mann KG: The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979, 254: 10952-10962.
- Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC: The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980, 255: 274-283.
- Esmon CT: The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979, 254: 964-973.
- Nesheim ME, Myrmel KH, Hibbard L, Mann KG: Isolation and characterization of single chain bovine factor V. J Biol Chem 1979, 254: 508-517.
- Laki K, Gladner JA: Chemistry and Physiology of the Fibrinogen-Fibrin Transition. Physiol Rev 1964, 44: 127-160.
- Doolittle RF: Structural aspects of the fibrinogen to fibrin conversion. Adv Protein Chem 1973, 27: 1-109.View Article
- Lorand L, Downey J, Gotoh T, Jacobsen A, Tokura S: The transpeptidase system which crosslinks fibrin by gamma-glutamyle-episilon-lysine bonds. Biochem Biophys Res Commun 1968, 31: 222-230. 10.1016/0006-291X(68)90734-1View Article
- Doolittle RF, Chen R, Lau F: Hybrid fibrin: proof of the intermolecular nature of - crosslinking units. Biochem Biophys Res Commun 1971, 44: 94-100. 10.1016/S0006-291X(71)80163-8View Article
- Rezaie AR: Determinants of specificity of factor xa interaction with its physiological inhibitors. Mini Rev Med Chem 2006, 6: 859-865. 10.2174/138955706777935017View Article
- Ellis V, Scully M, MacGregor I, Kakkar V: Inhibition of human factor Xa by various plasma protease inhibitors. Biochim Biophys Acta 1982, 701: 24-31.View Article
- Kisiel W, Canfield WM, Ericsson LH, Davie EW: Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977, 16: 5824-5831. 10.1021/bi00645a029View Article
- Fay PJ, Smudzin TM, Walker FJ: Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991, 266: 20139-20145.
- Walker FJ: Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981, 256: 11128-11131.
- Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994, 269: 31869-31880.
- Esmon CT: The protein C pathway. Chest 2003, 124: 26S-32S. 10.1378/chest.124.3_suppl.26SView Article
- Castoldi E, Hackeng TM: Regulation of coagulation by protein S. Curr Opin Hematol 2008, 15: 529-536. 10.1097/MOH.0b013e328309ec97View Article
- Meijers JC, Herwald H: Protein C inhibitor. Semin Thromb Hemost 2011, 37: 349-354. 10.1055/s-0031-1276583View Article
- Rezaie AR, Cooper ST, Church FC, Esmon CT: Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995, 270: 25336-25339. 10.1074/jbc.270.43.25336View Article
- Esmon CT: Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009, 23: 225-229. 10.1016/j.blre.2009.07.002View Article
- Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993, 90: 1004-1008. 10.1073/pnas.90.3.1004View Article
- Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369: 64-67. 10.1038/369064a0View Article
- Krishnaswamy S, Williams EB, Mann KG: The binding of activated protein C to factors V and Va. J Biol Chem 1986, 261: 9684-9693.
- Yu S, Zhang L, Jhingan A, Christiansen WT, Castellino FJ: Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX. Biochemistry 1994, 33: 823-831. 10.1021/bi00169a025View Article
- Mesters RM, Heeb MJ, Griffin JH: A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry 1993, 32: 12656-12663. 10.1021/bi00210a014View Article
- Segers K, Dahlback B, Rosing J, Nicolaes GA: Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin. J Biol Chem 2008, 283: 22573-22581. 10.1074/jbc.M801724200View Article
- Yegneswaran S, Kojima Y, Nguyen PM, Gale AJ, Heeb MJ, Griffin JH: Factor Va residues 311–325 represent an activated protein C binding region. J Biol Chem 2007, 282: 28353-28361. 10.1074/jbc.M704316200View Article
- Nicolaes GA, Bock PE, Segers K, Wildhagen KC, Dahlback B, Rosing J: Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 2010, 285: 22890-22900. 10.1074/jbc.M110.131029View Article
- Kalafatis M, Bertina RM, Rand MD, Mann KG: Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995, 270: 4053-4057. 10.1074/jbc.270.8.4053View Article
- Kalafatis M, Mann KG: Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993, 268: 27246-27257.
- Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J: Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270: 21158-21166. 10.1074/jbc.270.36.21158View Article
- Mann KG, Hockin MF, Begin KJ, Kalafatis M: Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 1997, 272: 20678-20683. 10.1074/jbc.272.33.20678View Article
- Hockin MF, Cawthern KM, Kalafatis M, Mann KG: A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. Biochemistry 1999, 38: 6918-6934. 10.1021/bi981966eView Article
- Kim PY, Nesheim ME: Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost 2010, 104: 61-70. 10.1160/TH09-09-0650View Article
- Nesheim ME, Canfield WM, Kisiel W, Mann KG: Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem 1982, 257: 1443-1447.
- Norstrom EA, Tran S, Steen M, Dahlback B: Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 2006, 281: 31486-31494. 10.1074/jbc.M606441200View Article
- Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, Schwarz HP, Tans G: Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270: 27852-27858. 10.1074/jbc.270.46.27852View Article
- Suzuki K, Stenflo J, Dahlback B, Teodorsson B: Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983, 258: 1914-1920.
- Tran S, Norstrom E, Dahlback B: Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 2008, 283: 6648-6655. 10.1074/jbc.M708036200View Article
- Yegneswaran S, Nguyen PM, Gale AJ, Griffin JH: Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. Thromb Haemost 2009, 101: 55-61.
- Egan JO, Kalafatis M, Mann KG: The effect of Arg306– > Ala and Arg506– > Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 1997, 6: 2016-2027. 10.1002/pro.5560060922View Article
- Nicolaes GA, Sorensen KW, Friedrich U, Tans G, Rosing J, Autin L, Dahlback B, Villoutreix BO: Altered inactivation pathway of factor Va by activated protein C in the presence of heparin. Eur J Biochem 2004, 271: 2724-2736. 10.1111/j.1432-1033.2004.04201.xView Article
- Danforth CM, Orfeo T, Mann KG, Brummel-Ziedins KE, Everse SJ: The impact of uncertainty in a blood coagulation model. Math Med Biol 2009, 26: 323-336. 10.1093/imammb/dqp011View Article
- Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta 1979, 571: 333-342. 10.1016/0005-2744(79)90103-7View Article
- Nesheim ME, Eid S, Mann KG: Assembly of the prothrombinase complex in the absence of prothrombin. J Biol Chem 1981, 256: 9874-9882.
- Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994, 269: 23367-23373.
- Hockin MF, Jones KC, Everse SJ, Mann KG: A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002, 277: 18322-18333. 10.1074/jbc.M201173200View Article
- Krishnaswamy S, Jones KC, Mann KG: Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988, 263: 3823-3834.
- Campbell JE, Brummel-Ziedins KE, Butenas S, Mann KG: Cellular regulation of blood coagulation: a model for venous stasis. Blood 2010, 116: 6082-6091. 10.1182/blood-2010-01-266395View Article
- Odegaard B, Mann K: Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem 1987, 262: 11233-11238.
- Barhoover MA, Kalafatis M: Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C. Blood Coagul Fibrinolysis 2011, 22: 317-324. 10.1097/MBC.0b013e3283456c4eView Article
- Everse SJ, Adams TE, Mann KG: A molecular model of the human prothrombinase complex. In Recent Advances in Thrombosis and Hemostasis. Volume 21. Edited by: Tanaka K, Davie EW. Springer, Tokyo; 2008:107-132.
- Autin L, Steen M, Dahlback B, Villoutreix BO: Proposed structural models of the prothrombinase (FXa-FVa) complex. Proteins 2006, 63: 440-450. 10.1002/prot.20848View Article
- Lee CJ, Lin P, Chandrasekaran V, Duke RE, Everse SJ, Perera L, Pedersen LG: Proposed structural models of human factor Va and prothrombinase. J Thromb Haemost 2008, 6: 83-89.View Article
- Kamata K, Kawamoto H, Honma T, Iwama T, Kim SH: Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci U S A 1998, 95: 6630-6635. 10.1073/pnas.95.12.6630View Article
- Adams TE, Hockin MF, Mann KG, Everse SJ: The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U S A 2004, 101: 8918-8923. 10.1073/pnas.0403072101View Article
- Zaitseva I, Zaitsev V, Card G, Moshkov K, Bax B, Ralph A, Lindley P: The X-ray structure of human serum ceruloplasmin at 3.1 angstrom: Nature of the copper centres. J Biol Inorg Chem 1996, 1: 15-23. 10.1007/s007750050018View Article
- Guinto ER, Esmon CT: Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984, 259: 13986-13992.
- Shaw AW, Pureza VS, Sligar SG, Morrissey JH: The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007, 282: 6556-6563.View Article
- Higgins DL, Mann KG: The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983, 258: 6503-6508.
- Bloom JW, Nesheim ME, Mann KG: Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979, 18: 4419-4425. 10.1021/bi00587a023View Article
- Lu Y, Nelsestuen GL: Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: implications for protein–membrane contact. Biochemistry 1996, 35: 8193-8200. 10.1021/bi960280oView Article
- Krishnaswamy S, Mann KG: The binding of factor Va to phospholipid vesicles. J Biol Chem 1988, 263: 5714-5723.
- Smirnov MD, Safa O, Regan L, Mather T, Stearns-Kurosawa DJ, Kurosawa S, Rezaie AR, Esmon NL, Esmon CT: A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem 1998, 273: 9031-9040. 10.1074/jbc.273.15.9031View Article
- Morrissey JH, Pureza V, Davis-Harrison RL, Sligar SG, Rienstra CM, Kijac AZ, Ohkubo YZ, Tajkhorshid E: Protein-membrane interactions: blood clotting on nanoscale bilayers. J Thromb Haemost 2009,7(Suppl 1):169-172.View Article
- Bakker HM, Tans G, Janssen-Claessen T, Thomassen MC, Hemker HC, Griffin JH, Rosing J: The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992, 208: 171-178. 10.1111/j.1432-1033.1992.tb17171.xView Article
- Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT: On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995, 95: 309-316. 10.1172/JCI117657View Article
- Smirnov MD, Ford DA, Esmon CT, Esmon NL: The effect of membrane composition on the hemostatic balance. Biochemistry 1999, 38: 3591-3598. 10.1021/bi982538bView Article
- Jordan SW, Chaikof EL: Simulated surface-induced thrombin generation in a flow field. Biophys J 2011, 101: 276-286. 10.1016/j.bpj.2011.05.056View Article
- Bungay SD, Gentry PA, Gentry RD: A mathematical model of lipid-mediated thrombin generation. Math Med Biol 2003, 20: 105-129. 10.1093/imammb/20.1.105View Article
- Qiao YH, Xu CQ, Zeng YJ, Xu XH, Zhao H, Xu H: The kinetic model and simulation of blood coagulation–the kinetic influence of activated protein C. Med Eng Phys 2004, 26: 341-347. 10.1016/j.medengphy.2004.01.003View Article
- Qiao YH, Liu JL, Zeng YJ: A kinetic model for simulation of blood coagulation and inhibition in the intrinsic path. J Med Eng Technol 2005, 29: 70-74. 10.1080/03091900410001709079View Article
- Anand M, Rajagopal K, Rajagopal KR: A model for the formation, growth, and lysis of clots in quiescent plasma. A comparison between the effects of antithrombin III deficiency and protein C deficiency. J Theor Biol 2008, 253: 725-738. 10.1016/j.jtbi.2008.04.015View Article
- Kuharsky AL, Fogelson AL: Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J 2001, 80: 1050-1074. 10.1016/S0006-3495(01)76085-7View Article
- Fogelson AL, Tania N: Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 2005, 34: 91-108. 10.1159/000089930View Article
- Ermakova EA, Panteleev MA, Shnol EE: Blood coagulation and propagation of autowaves in flow. Pathophysiol Haemost Thromb 2005, 34: 135-142. 10.1159/000089933View Article
- Kastrup CJ, Shen F, Runyon MK, Ismagilov RF: Characterization of the threshold response of initiation of blood clotting to stimulus patch size. Biophys J 2007, 93: 2969-2977. 10.1529/biophysj.107.109009View Article
- Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, Butylin AA, Saenko EL, Ataullakhanov FI: Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006, 90: 1489-1500. 10.1529/biophysj.105.069062View Article
- Luan D, Zai M, Varner JD: Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 2007, 3: e142. 10.1371/journal.pcbi.0030142View Article
- Wagenvoord R, Hemker PW, Hemker HC: The limits of simulation of the clotting system. J Thromb Haemost 2006, 4: 1331-1338. 10.1111/j.1538-7836.2006.01967.xView Article
- Bajaj SP, Mann KG: Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem 1973, 248: 7729-7741.
- Krishnaswamy S, Church WR, Nesheim ME, Mann KG: Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem 1987, 262: 3291-3299.
- Katzmann JA, Nesheim ME, Hibbard LS, Mann KG: Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A 1981, 78: 162-166. 10.1073/pnas.78.1.162View Article
- Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD: A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977, 16: 2806-2810. 10.1021/bi00631a035View Article
- Pryzdial EL, Mann KG: The association of coagulation factor Xa and factor Va. J Biol Chem 1991, 266: 8969-8977.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.